Abstract P333: Influence Of RSK2 On Blood Pressure In Aging

Hypertension (HTN) is highly prevalent and is a significant risk factor for CVD. Excessive vasoconstriction contributes to HTN. Recently, p90 ribosomal S6 kinase, isoform 2 (RSK2) signaling has been shown to play a significant role in the regulation of basal vascular tone and BP control by phosphorylating RLC20 to promote smooth muscle contractility. Young adult Rsk2 KO mice have lower BP than WT littermates. Here, we examine the role of RSK2 in a geriatric HTN mouse model. Male >2-year old WT and Rsk2 KO mice underwent daily BP measurements using tail cuff manometry. After 2 weeks of training, baseline (BL) BP was recorded, followed by 2 weeks of HTN induced by 20 mg/kg/day of L-N G -Nitroarginine methyl ester (L-NAME) via drinking water. Echocardiographic studies were performed at BL. WT mice had significant mortality (7 of 11 died), not seen in KO (1 of 8 died). At BL, WT mice had a significantly higher SBP compared to KOs (123±10 vs. 99±12 mmHg). L-NAME elevated SBP in WT but not KO mice (137±2 vs. 97±8 mmHg). Echocardiographic studies at BL showed no differences between genotypes. However, when ejection fraction (EF) was correlated with SBP, EF was negatively correlated with SBP in WT (-0.94 %/mmHg, p = 0.046, R 2 = 0.59, n = 6) but not KO mice (p = 0.15, n = 7). Clinically, HTN-associated mortality and morbidity primarily affects older populations. Here, we show that the loss of RSK2 reduces BP in geriatric mice, similar to findings in young adult mice, and that it also abolished the hypertensive effects of L-NAME. Aged Rsk2 KO mice appear to be protected from cardiovascular effects of aging. RSK2 is a potential target for pharmacologic inhibition to treat HTN and related risks in geriatric populations.